News Conference News EAS 2022 Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively Michael O'Riordan May 27, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2021 High Ischemic Risk and Bleeding Risk: A Delicate Balance Post-PCI Michael O'Riordan June 08, 2021
News Conference News EAS 2021 For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short Michael O'Riordan June 03, 2021
News Conference News EAS 2020 Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank Michael O'Riordan October 07, 2020
News Conference News EAS 2019 Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019
News Conference News EAS 2018 EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms Yael L. Maxwell May 11, 2018
News Conference News EAS 2018 Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention Yael L. Maxwell May 07, 2018
News Conference News EAS 2016 Preservation of LDL Cholesterol Targets for Lipid Lowering in New European Guidance Gets Blessing of Prevention Experts Yael L. Maxwell June 06, 2016
News Conference News EAS 2016 Statin-Associated Muscle Symptoms: Real or ‘Artificial,’ Physicians Should Take Time to Manage Patients Yael L. Maxwell June 01, 2016